Refractory focal epilepsy (drug-resistant focal onset seizures)
RAPPRapport Therapeutics IncCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for RAP-219 in Refractory focal epilepsy (drug-resistant focal onset seizures). The expected timing is based on the latest available company guidance and may change.
04/01/26:- Phase 2a 8-week follow-up data will be presented at AAN on April 21, 2026. 04/21/26:- AAN showed sustained Ph2a week 9-16 efficacy. FOCUS 1/2 Ph3 start Q2 2026; OLE initial data H2 2026. 05/07/26:- New Ph2a FOS follow-up data show seizure reductions; Ph3 start Q2 2026, OLE data H2 2026, Tenacia Greater China deal. 08/05/26:- FOCUS 1/2 enrolling; open-label safety data expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.